{"filing":{"accession_number":"0000899923-26-000059","cik":"0000899923","ticker":"MYGN","company_name":"MYRIAD GENETICS INC","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"mygn-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000059/mygn-20260604.htm"},"events":[{"id":6713,"run_id":5877,"accession_number":"0000899923-26-000059","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Myriad Genetics held its Annual Meeting of Stockholders on June 4, 2026, with stockholders voting on five proposals: election of three Class III directors (Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D.), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2012 Employee Stock Purchase Plan increasing authorized shares by 4,000,000, and approval of the new 2026 Employee, Director and Consultant Equity Incentive Plan with 8,463,567 shares available for issuance. All five proposals passed with detailed vote tallies disclosed.","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4216,"accession_number":"0000899923-26-000059","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses stockholder approval of two equity compensation plans: an amendment to the 2012 Employee Stock Purchase Plan increasing authorized shares by 4,000,000, and adoption of a new 2026 Employee, Director and Consultant Equity Incentive Plan with 8,463,567 shares available for issuance. These are compensatory arrangements for directors, officers, and employees that materially affect equity incentive structures and would be relevant to investor assessment of dilution and executive compensation practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:50:23.790823+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4217,"accession_number":"0000899923-26-000059","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Myriad Genetics' Annual Meeting of Stockholders held on June 4, 2026, including voting outcomes on five proposals: election of three Class III directors (Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D.), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2012 Employee Stock Purchase Plan, and approval of the 2026 Employee, Director and Consultant Equity Incentive Plan. The disclosure provides detailed vote tallies (for, against, abstained, broker non-votes) for each proposal, all of which passed. This is a quintessential shareholder vote results disclosure required under Item 5.07 and is material to investors as it confirms director elections and equity plan approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:50:23.790823+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4216,"accession_number":"0000899923-26-000059","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses stockholder approval of two equity compensation plans: an amendment to the 2012 Employee Stock Purchase Plan increasing authorized shares by 4,000,000, and adoption of a new 2026 Employee, Director and Consultant Equity Incentive Plan with 8,463,567 shares available for issuance. These are compensatory arrangements for directors, officers, and employees that materially affect equity incentive structures and would be relevant to investor assessment of dilution and executive compensation practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:50:23.790823+00:00","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-06-04"},{"id":4217,"accession_number":"0000899923-26-000059","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Myriad Genetics' Annual Meeting of Stockholders held on June 4, 2026, including voting outcomes on five proposals: election of three Class III directors (Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D.), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2012 Employee Stock Purchase Plan, and approval of the 2026 Employee, Director and Consultant Equity Incentive Plan. The disclosure provides detailed vote tallies (for, against, abstained, broker non-votes) for each proposal, all of which passed. This is a quintessential shareholder vote results disclosure required under Item 5.07 and is material to investors as it confirms director elections and equity plan approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:50:23.790823+00:00","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-06-04"}]}